rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Mustang Bio, Inc.

MBIO · Nasdaq

Health CareBiotechnologyNot moving yet

MBIO stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 41.3% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$237
Insider sales, 12 months
$241
Officials’ trades on record
0
Institutions holding
22 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$224$0$220Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months2
Buyers · sellers1 · 2

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders22+1 on the quarter
New · exited5 · 4
Reported value$368K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Kestra Advisory Services, LLCadded · filed 28 Jul 2026196,991$138K+20,949+11.9%
BlackRock, Inc.unchanged · filed 7 Aug 202684,745$59K00.0%
CITADEL ADVISORS LLCadded · filed 14 Aug 202659,459$42K+6,259+11.8%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202642,240$30K-50,550−54.5%
CFO4Life Group, LLCadded · filed 12 Aug 202633,510$24K+13,049+63.8%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202632,120$23K00.0%
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 202625,704$18K00.0%
XTX Topco Ltdnew · filed 14 Aug 202614,648$10K+14,648
TWO SIGMA SECURITIES, LLCnew · filed 14 Aug 202613,742$9,647+13,742
SUSQUEHANNA INTERNATIONAL GROUP, LLPnew · filed 14 Aug 202613,664$9,592+13,664
31 Dec 2024 – 30 Jun 2026
21222Dec 24Jun 25Sep 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Manuel Litchman Company insiderPresident, CEO and Interim CFO · last 24 Apr 202614 · 1
Fortress Biotech, Inc. Company insider10% owner · last 2 Jan 20260 · 0
Adam J. Chill Company insiderDirector · last 30 Dec 20250 · 1
David Jin Company insiderDirector · last 30 Dec 20251 · 0
Neil Herskowitz Company insiderDirector · last 30 Dec 20251 · 1
Lindsay A. Rosenwald Company insiderDirector · last 5 Jul 20235 · 0
Michael J. Zelefsky Company insiderDirector · last 5 Jul 20230 · 0
Michael S. Weiss Company insiderDirector · last 5 Jul 20230 · 0
Brian Achenbach Company insiderSVP, Fin. & Corp. Controller · last 14 Dec 20213 · 8

Same industry

MRNA ModernaLeading+154%
IOVA Iovance BiotherapeuticsLeading+133%
ABCL AbCellera BiologicsLeading+61%
ENTX Entera BioLeading+49%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+46%
HELP Helus PharmaLeading+37%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-25.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$17.3M
Free cash flowFY 2024 · to 31 Dec 2024−$11.4M

Analyst forecasts

No analyst forecasts yet.